{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001622","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.427173+00:00","generated_at":"2026-06-08T23:27:13.984078+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alnylam Q3 2023 net product revenues $313M (+35% YoY); FDA CRL for ONPATTRO cardiomyopathy","bullets":["Q3 net product revs $313M (+35% YoY); GAAP net income $147.8M ($1.15 diluted EPS) vs loss of $405.9M in Q3 2022.","FDA issued Complete Response Letter for patisiran (ONPATTRO) sNDA for ATTR cardiomyopathy.","Positive topline results from KARDIA-1 Phase 2 study of zilebesiran in hypertension; entered global collaboration with Roche.","Updated 2023 guidance: collaboration & royalty rev $575-625M; net product rev reiterated at $1,200-1,285M."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001622","json":"https://secwatch.observer/filing/0001157523-23-001622.json","markdown":"https://secwatch.observer/filing/0001157523-23-001622.md","text":"https://secwatch.observer/filing/0001157523-23-001622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/0001157523-23-001622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/a53737945.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:27:13.984078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"511c0a2db4a99733d9818d2ddc373110eae7f518","claim":"ALNYLAM PHARMACEUTICALS, INC. reported third quarter ended September 30, 2023 results: revenue $313 Million, net income $147,753, EPS $1.18.","evidence_excerpt":"Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity − Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth Compared to Q3 2022 –","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/0001157523-23-001622-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$313 Million"},{"label":"Net income","value":"$147,753"},{"label":"EPS","value":"$1.18"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}